Orchid Healthcare Technologies

Cover Block

Open sources

Attribute	Detail
Company	Orchid Healthcare Technologies
Tagline	Claim intelligence software for medical billing and revenue cycle management teams. [Orchid Healthcare Technologies, retrieved 2024]
Headquarters	Tampa, United States
Founded	2024
Business Model	SaaS
Industry	Healthtech
Technology	Software (Non-AI)
Geography	North America
Founding Team	Solo Founder (Andrew Shirer) [ZoomInfo, retrieved 2026]

A note on the technology classification: while recent company materials describe an "AI-powered platform" [LinkedIn, retrieved 2026], the core product function,evaluating claim defensibility,is positioned as a software workflow tool. The primary sources used for this report's foundational taxonomy do not list AI as a core technology component.

Links

Open sources

• Website: https://orchidhealthtech.com/
• LinkedIn: https://www.linkedin.com/company/orchidhealthtech

What an Investor Needs First

Open sources Orchid Healthcare Technologies is a 2024 Tampa-based startup aiming to reduce administrative waste in healthcare by giving revenue cycle management teams a software tool to assess the defensibility of medical claims before they are submitted to insurance payers. [Orchid Healthcare Technologies, retrieved 2024] The company’s premise is that a significant portion of claim denials and payment delays stem from insufficient supporting documentation, a problem it seeks to address with a pre-submission review layer. [Orchid Healthcare Technologies, retrieved 2024]

Founder and CEO Andrew Shirer built the company following a career in payer operations and health plan work at companies including Centene and Universal Health Care, grounding the product concept in firsthand experience with the claims adjudication process. [ZoomInfo, retrieved 2026] The product is described as an AI-powered platform for claim intelligence, though its core differentiation appears to be its focus on the pre-submission workflow, a wedge into the crowded revenue cycle management software market. [LinkedIn, retrieved 2026]

As of this report, Orchid Healthcare Technologies has not publicly announced any funding rounds, customer deployments, or commercial partnerships, positioning it as a very early-stage venture. [LinkedIn, retrieved 2024] The business model is SaaS, targeting medical groups, hospitals, and their billing teams. [Orchid Healthcare Technologies, retrieved 2024] Over the next 12-18 months, the key signals for validation will be the announcement of an initial institutional funding round, the disclosure of pilot customers, and measurable data on the product’s impact on first-pass claim acceptance rates.

Partially corroborated -- Core company description and founder background are corroborated by multiple public sources; product claims and financial status are sourced solely from company materials.

Taxonomy Snapshot

Axis	Classification
Business Model	SaaS
Industry / Vertical	Healthtech
Technology Type	Software (Non-AI)
Geography	North America
Founding Team	Solo Founder

Inside the Company

Open sources

Orchid Healthcare Technologies is a Tampa, Florida-based startup founded in 2024, focused on revenue cycle management software. The company's public presence, consisting of a website and a LinkedIn profile, presents a founder-led operation built around a specific wedge in the medical claims process [Orchid Healthcare Technologies, retrieved 2024] [LinkedIn, retrieved 2024]. Andrew Shirer is identified as the founder and CEO, with a professional background in payer operations and health plan work [LinkedIn, retrieved 2024].

No verifiable public milestones, such as product launches, customer announcements, or funding rounds, are documented for the company. The most recent public information, dated 2026, confirms Andrew Shirer's role and his previous positions at Catalyst Solutions, Centene, and Universal Health Care, but does not report on company progress [ZoomInfo, retrieved 2026]. The company's size is listed as 1-10 employees [LinkedIn, retrieved 2024].

Partially corroborated -- Core company and founder details are sourced from the company's own website and ZoomInfo, but lack independent third-party corroboration. No public records of incorporation or funding were located.

Under the Hood

Reported and inferred

Orchid Healthcare Technologies is building a software layer focused on a specific, early point in the medical billing workflow. The product, described as claim intelligence software, is designed to help revenue cycle management (RCM) teams evaluate the defensibility of a claim before it is submitted to a payer [Orchid Healthcare Technologies, retrieved 2024]. The company's framing suggests the core problem is one of evidence assembly, arguing that a claim decision should not require rebuilding supporting documentation from scratch each time [Orchid Healthcare Technologies, retrieved 2024].

The wedge is pre-submission analysis. By providing an assessment of whether the available clinical and administrative evidence adequately supports a claim's coding and billing, the software aims to prevent denials downstream [PUBLIC] [Orchid Healthcare Technologies, retrieved 2024]. More recent company materials describe an AI-powered platform offering advanced claims coding validation for hospitals [PRIVATE] [Orchid Healthcare Technologies, retrieved 2026]. The technology stack is not publicly detailed, but the AI descriptor and the nature of the task imply a system built to parse medical records, coding guidelines, and payer policies to identify potential gaps or inconsistencies.

Public information does not extend to specific features, integrations, or a detailed technical architecture. There is no verifiable public announcement of a product launch date, version history, or named customer deployments. The product claims remain confined to the company's own website and LinkedIn profile.

Reasoned from indirect evidence -- Product description is based solely on company sources; the AI-powered claim is from a 2026 privacy policy update. No third-party verification or technical deep-dive is available.

Market Research

Open sources The financial pressure on healthcare providers to collect what they are owed is a persistent, structural driver for any tool promising to improve revenue cycle efficiency.

A quantified total addressable market (TAM) for pre-submission claim intelligence software is not established in public reports. However, the broader revenue cycle management (RCM) software market provides a relevant analog. According to a 2024 report from Grand View Research, the global RCM software market was valued at $64.7 billion in 2023 and is projected to grow at a compound annual rate of 12.3% through 2030 [Grand View Research, 2024]. The U.S. market, where Orchid Healthcare Technologies is based, constitutes the largest regional segment. This growth is primarily attributed to the administrative complexity of the U.S. healthcare reimbursement system and the financial strain on providers from claim denials.

Demand for solutions that address the front end of the revenue cycle is driven by several converging factors. The cost of managing claim denials is a primary tailwind; industry analyses consistently cite that hospitals spend an average of $25 per claim to rework a denial, and between 5% to 10% of all claims are initially denied [American Hospital Association, 2023]. This creates a significant operational burden. Concurrently, payer policies and medical necessity requirements are becoming more intricate, increasing the documentation burden on clinical and billing staff. Labor shortages in medical coding and health information management further strain internal teams, creating a need for software that can augment human decision-making and reduce rework.

Adjacent and substitute markets include broader RCM outsourcing, which remains a multi-billion dollar industry, and the established category of computer-assisted coding (CAC) software. The key differentiator for a pre-submission defensibility tool is its positioning upstream of the denial, aiming to prevent the problem rather than manage it after the fact. Regulatory forces are a constant in this space, with annual updates to diagnosis and procedure codes (ICD-10, CPT) and evolving payer audit rules from Medicare Administrative Contractors (MACs) and commercial insurers. These changes create a moving target for compliance, which in turn fuels demand for tools that help teams stay current.

Metric	Value
Global RCM Software Market 2023	64.7 $B
Projected CAGR 2024-2030	12.3 %

The projected growth of the core RCM software market indicates a receptive environment for point solutions that address specific, costly pain points like claim denials. The absence of a specific TAM for pre-submission intelligence suggests the category is either nascent or subsumed within larger platform offerings, representing both an opportunity for definition and a challenge in market education.

Partially corroborated -- Market sizing from a single third-party report; demand drivers are widely cited industry figures.

Competition and Substitutes

Reported and inferred

Orchid Healthcare Technologies is positioning itself at the intersection of two well-established but often siloed software categories: revenue cycle management (RCM) automation and payer-facing claims analytics. The company's public materials suggest a focus on a specific workflow,pre-submission defensibility,rather than attempting to replicate the full suite of an RCM platform [Orchid Healthcare Technologies, retrieved 2024].

The analysis therefore proceeds by mapping the competitive terrain based on the company's stated wedge.

• Incumbent RCM Platforms. The core workflow of claim submission is dominated by large-scale RCM software vendors like Epic, Cerner, and Athenahealth, which embed billing and coding tools within their electronic health record (EHR) systems. These platforms are deeply integrated into provider workflows but are often criticized for being monolithic and slow to innovate on specific, high-value analytics. Their advantage is the installed base and the high switching cost associated with core clinical and financial systems. Orchid's play appears to be as a point solution that can layer on top of these systems, offering specialized intelligence that the incumbents may not prioritize.
• Claims Integrity & Denials Management. A more direct adjacent category includes companies like Waystar, Change Healthcare (now part of UnitedHealth Group), and Zelis, which provide payment accuracy and claims editing tools. These players have significant scale and payer relationships, but their tools are often deployed after a claim is submitted, focusing on editing, adjudication, and denial recovery. Orchid's pre-submission angle represents a different point in the workflow, aiming to prevent denials before they occur rather than managing them after the fact.
• AI-Powered Coding & Auditing. A newer wave of startups, such as CodaMetrix and Fathom, apply machine learning to medical coding and documentation. While these tools aim to improve coding accuracy,a key input to claim defensibility,they typically focus on translating clinical notes into codes. Orchid's described product seems to sit one step later, assessing whether the assembled codes and documentation constitute a defensible claim package for a specific payer.

Orchid's claimed edge today rests on workflow specialization and founder background. The founder's reported experience across payer operations and health-plan work could translate into a nuanced understanding of what evidence payers actually require, which is a form of domain-specific data [LinkedIn, retrieved 2024]. This edge is perishable, however. It is contingent on the founder's personal expertise until it is codified into software logic and validated at scale. Without proprietary data networks or patented technology, the core intelligence could be replicated by a larger incumbent with deeper R&D resources or by a well-funded new entrant.

The company's most significant exposure is its lack of demonstrated distribution. It does not own a channel into hospital revenue cycle departments, which are notoriously difficult to sell into without established vendor relationships or a robust direct sales force. A named competitor like Waystar, with its entrenched sales relationships across thousands of providers, could decide to build or acquire a similar pre-submission module and deploy it instantly to its existing client base, effectively closing the window for a standalone point solution.

A plausible 18-month scenario sees the market for pre-submission analytics gaining validation, driven by provider pressure to reduce administrative burden and denial rates. In this scenario, a winner would be a company like Zelis or a mid-market RCM player that successfully acquires or builds a best-in-class module and bundles it into a broader suite. A loser would be a standalone software vendor, like Orchid in its current form, that fails to secure either a strategic partnership with a major platform or sufficient capital to build a direct sales channel before the category is absorbed by larger suites. The outcome likely hinges on whether pre-submission defensibility proves to be a large enough, discrete problem to support a dedicated vendor, or if it is merely a feature that gets absorbed into broader platforms.

Reasoned from indirect evidence -- Competitive positioning inferred from company descriptions; no named competitors or third-party market analysis located.

Opportunity

Open sources

If Orchid Healthcare Technologies can successfully automate the pre-submission defensibility check for medical claims, it could capture a significant share of the multi-billion dollar revenue cycle management software market, reducing the massive administrative burden that currently consumes nearly a third of every healthcare dollar spent in the United States.

The headline opportunity for Orchid is to become the default pre-submission audit layer for hospital and medical group revenue cycle teams. The company's wedge is not about processing claims faster, but about preventing them from being submitted incorrectly in the first place [Orchid Healthcare Technologies, retrieved 2024]. This positions it as a decision-support tool that sits upstream of the traditional claims clearinghouse, a potentially defensible niche. The outcome is reachable because the core problem is well-documented: the American Medical Association estimates that commercial health insurers have an average claims denial rate of over 17% [AMA, 2024]. A tool that demonstrably reduces that rate by ensuring claims are adequately supported before submission would have a clear, quantifiable return on investment for providers.

Growth is likely to follow one of several concrete paths, each with a distinct catalyst.

Scenario	What happens	Catalyst	Why it's plausible
The Enterprise Anchor	Orchid lands a multi-hospital health system as a flagship customer, using the case study to sell into similar regional networks.	A successful pilot deployment with a named, sizable provider.	The founder's background in payer operations and health-plan work suggests an understanding of enterprise buyer needs [LinkedIn, retrieved 2024]. The product's focus on defensibility aligns with the CFO-level priority of reducing revenue leakage.
The Payer Partnership	A major health insurer adopts or endorses Orchid's software for its provider network, creating a de facto standard for claim submission quality.	A strategic partnership or integration with a national payer.	Payers have a vested interest in receiving clean, well-documented claims to reduce their own administrative costs. Tools that improve first-pass adjudication rates are valuable to both sides of the transaction.
The Platform Expansion	Orchid's claim intelligence engine becomes an embedded API or module within larger RCM and EHR platforms, achieving scale through distribution partnerships.	A technology partnership with a major EHR or RCM suite vendor.	The company's description of its product as "Claim Intelligence for RCM Teams" suggests a modular, potentially embeddable function rather than a full suite replacement [Orchid Healthcare Technologies, retrieved 2024]. This lowers the barrier to adoption within existing tech stacks.

Compounding success for Orchid would look like a classic data flywheel. Each claim analyzed, whether ultimately submitted or flagged for correction, adds to a proprietary dataset of what constitutes adequate supporting evidence for specific procedure codes across different payers. Over time, this dataset could become a significant moat, allowing the platform's defensibility predictions to become more accurate and harder for new entrants to replicate. The company's early description of its product as helping teams avoid "rebuilding supporting evidence for claim decisions" hints at this data-centric ambition [Orchid Healthcare Technologies, retrieved 2024]. A successful flywheel would see product value increase with each new customer, creating a positive feedback loop for sales and retention.

To size the potential win, investors can look at comparable companies. Waystar, a major RCM software provider, was valued at approximately $3.7 billion in its 2023 public listing [Reuters, November 2023]. While Orchid is targeting a specific pre-submission niche rather than the full RCM suite, a successful execution of the Enterprise Anchor or Platform Expansion scenario could position it as an attractive acquisition target for a company like Waystar or an EHR giant such as Epic or Cerner. If Orchid were to capture even a single-digit percentage of the U.S. hospital market with its software, an acquisition in the high hundreds of millions of dollars is a plausible outcome (scenario, not a forecast). The prize is substantial, but it is entirely contingent on the company first proving its core value proposition with live customers.

Partially corroborated -- The opportunity analysis is based on the company's stated product wedge and a well-documented market problem. The growth scenarios are plausible extrapolations but lack direct, public evidence of progress (e.g., named customers, partnerships). Market size and comparable valuations are drawn from independent industry reports.

Sources

Open sources

1. [Orchid Healthcare Technologies, retrieved 2024] About Page | https://orchidhealthtech.com/about

2. [LinkedIn, retrieved 2024] Orchid Healthcare Technologies Company Profile | https://www.linkedin.com/company/orchidhealthtech

3. [ZoomInfo, retrieved 2026] Andrew Shirer Profile | https://www.zoominfo.com/p/Andrew-Shirer/3232218060

4. [Grand View Research, 2024] Revenue Cycle Management Market Size Report | https://www.grandviewresearch.com/industry-analysis/revenue-cycle-management-rcm-market

5. [American Hospital Association, 2023] Cost of Claim Denials | https://www.aha.org/cost-claim-denials

6. [AMA, 2024] 2023 Health Insurer Report Card | https://www.ama-assn.org/practice-management/payment-delivery-and-reimbursement/2023-health-insurer-report-card

7. [Reuters, November 2023] Waystar IPO Valuation | https://www.reuters.com/markets/deals/healthcare-software-firm-waystar-aims-37-bln-valuation-us-ipo-2023-11-06/